Den europeiske union -
norsk -
EMA (European Medicines Agency)
copiktra
secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastiske midler - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies. follicular lymphoma (fl) that is refractory to at least two prior systemic therapies.
Norge -
norsk -
Statens legemiddelverk
metadon dne 5 mg/ ml
dne pharma - metadonhydroklorid - mikstur, oppløsning - 5 mg/ ml
Norge -
norsk -
Statens legemiddelverk
metadon dne 1 mg/ ml
dne pharma - metadonhydroklorid - mikstur, oppløsning - 1 mg/ ml
Norge -
norsk -
Statens legemiddelverk
metadon dne 2 mg/ ml
dne pharma - metadonhydroklorid - mikstur, oppløsning - 2 mg/ ml
Den europeiske union -
norsk -
EMA (European Medicines Agency)
intuniv
takeda pharmaceuticals international ag ireland branch - guanfacin hydroklorid - attention deficit disorder med hyperaktivitet - antiadrenergic agents, centrally acting, antihypertensives, - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. intuniv må brukes som en del av en omfattende adhd behandling program, vanligvis inkludert psykologiske, pedagogiske og sosiale tiltak.
Norge -
norsk -
Statens legemiddelverk
flutikason cipla 125 mikrog/ dose
cipla europe nv - flutikasonpropionat - inhalasjonsaerosol, suspensjon - 125 mikrog/ dose
Norge -
norsk -
Statens legemiddelverk
flutikason cipla 250 mikrog/ dose
cipla europe nv - flutikasonpropionat - inhalasjonsaerosol, suspensjon - 250 mikrog/ dose
Norge -
norsk -
Statens legemiddelverk
rimactazid 150 mg / 75 mg
sandoz - københavn - rifampicin / isoniazid - tablett, filmdrasjert - 150 mg / 75 mg
Norge -
norsk -
Statens legemiddelverk
rimstar
sandoz - københavn - rifampicin / isoniazid / pyrazinamid / etambutolhydroklorid - tablett, filmdrasjert - 150 mg / 75 mg / 400 mg / 275 mg
Den europeiske union -
norsk -
EMA (European Medicines Agency)
tukysa
seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - antineoplastiske midler - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.